Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Belite BioBLTE +1.86%21 EV-to-EBIT is -53.92 as of Aug. 25, 2026. GuruFocus rates BLTE with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 376 Biotechnology companies, Belite Bio ranks worse than 265957.18% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Belite Bio's Enterprise Value for the quarter that ended in Jun. 2026 was $6,201.28 Mil.
Belite Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-112.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Belite Bio EV-to-EBIT Related Terms
Belite Bio EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Belite Bio's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Belite Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Belite Bio EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Belite Bio's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Belite Bio's EV-to-EBIT falls into.
Belite Bio's current Enterprise Value is $6,043.77 Mil.
Belite Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-112.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Belite Bio (BLTE) has a EV-to-EBIT of -53.92 as of Aug. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Belite Bio and its competitors. According to the industry distribution chart, Belite Bio ranks #999999 out of 376 companies in the Biotechnology industry.
Is Belite Bio's EV-to-EBIT too high?
Belite Bio's current EV-to-EBIT is -53.92. Based on the distribution chart, Belite Bio ranks #999999 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Belite Bio has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Belite Bio's EV-to-EBIT compare to CGON and LGND?
According to the Biotechnology industry distribution chart, Belite Bio ranks #999999 out of 376 companies for EV-to-EBIT. This places Belite Bio in the lower half of its industry. The industry median EV-to-EBIT is 16.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.28, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Belite Bio and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Belite Bio's current EV-to-EBIT is -53.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belite Bio stock overvalued right now?
Belite Bio (BLTE) has a current EV-to-EBIT of -53.92. The current EV-to-EBIT is -53.92. Belite Bio's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Belite Bio (BLTE), the current EV-to-EBIT is -53.92 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
21GF Score
Get the complete analysis for BLTE
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLTE has been successfully added to your 
